Neoadjuvant Herceptin in Patients With Breast Cancer

BREAST CANCER Clinical Trial

Official title:

A Phase II Study of the Effects of Herceptin in Patients With Locally Advanced HER-2/NEU Overexpressing Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00133796
• Other study ID #: H-10379
• Status: Terminated
• Phase: Phase 2
• First received: August 22, 2005
• Last updated: February 3, 2017
• Start date: October 2001
• Est. completion date: April 2007

Study information

• Verified date: February 2017
• Source: Baylor Breast Care Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purposes of this study are to better understand how Herceptin causes tumors to become smaller and to find out how effective Herceptin, together with chemotherapy, is in treating advanced breast cancer.

Description:

We want to determine the effects of Herceptin and to determine its efficacy in women with HER-2 overexpressing advanced breast cancer. The end-points will include the comparison of an array of histologic and molecular markers from sequential core biopsies of primary breast cancers of patients receiving Herceptin.

The other aim of this study would be to determine clinical response to therapy with Herceptin and Taxotere.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 40
• Est. completion date: April 2007
• Est. primary completion date: September 2005
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• All patients must be female.

• Informed consent must be signed.

• Women with locally advanced breast cancers or primary breast cancers with concomitant gross metastatic disease are eligible. Locally advanced cancers must be of clinical and/or radiologic size > 4 cm, and/or are deemed surgically inoperable.

• Her2/neu overexpressing tumors defined as HercepTest score of 3+, or >/= one-third of invasive tumor showing membranous staining, or fluorescence in situ hybridization (FISH) positive.

• Negative serum pregnancy test (bHCG) within 7 days of starting study, if of child-bearing potential.

• Kidney and liver function tests - all within 1.5 times of the institution's upper limit of normal.

• Performance status (World Health Organization [WHO] scale) < 2 and life expectancy > 6 months.

• Age > 18.

• No metastatic disease without concomitant primary breast cancer.

• No previous or current malignancies at other sites within the last 5 years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.

Exclusion Criteria:

• Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential.

• Severe underlying chronic illness or disease.

• Cardiomyopathy or baseline left ventricular ejection fraction (LVEF) < 50%.

• Patients on other investigational drugs while on study.

• Severe or uncontrolled hypertension defined as blood pressure (BP) > 180/100 on three separate occasions.

• History of congestive heart failure.

• History of coronary arterial disease.

Related Conditions & MeSH terms

• BREAST CANCER
• Breast Neoplasms

Intervention

Drug:
• Herceptin
IV

Locations

Country	Name	City	State
United States	Baylor Breast Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Mothaffar Rimawi	Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The effects of Herceptin and its efficacy in women with HER-2 overexpressing advanced breast cancer	A comparison of histologic and molecular markers from sequential core biopsies of primary breast cancers of patients receiving Herceptin	1 year
Secondary	To determine clinical response to therapy with Herceptin and Taxotere		one year